Renaissance Capital logo

Drugs Made In America Acquisition Priced, Nasdaq: DMAAU

Blank check company targeting pharmaceutical businesses in the US.

Industry: SPAC

Latest Trade: $10.11 0.00 (0.0%)

First Day Return: 0.0%

Return from IPO: +1.1%

Drugs Made In America Acquisition Corp. was incorporated as a blank check company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Our initial business combination and value creation strategy will be to identify, acquire and, after our initial business combination, assist in the growth of a pharmaceutical business in the United States. Our focus will be on the pharmaceutical sector. However, we are not limited to the pharmaceutical industry, or the named sectors, and we may pursue a business combination opportunity in any business or industry we choose and we may pursue a company with operations or opportunities outside of the United States. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry.
IPO Data
IPO Date 01/27/2025
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 20.0
Deal Size ($mm) $200
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Clear Street
Company Data
Headquarters Fort Lauderdale, FL, United States
Founded 2024
Employees at IPO 2

Drugs Made In America Acquisition (DMAAU) Performance

Created with Highcharts 10.3.2Chart context menuDMAAU vs. IPO Index (IPOUSA)28. Jan30. Jan3. Feb5. Feb9. Feb11. Feb13. Feb17. Feb19. Feb23. Feb25. Feb27. Feb3. Mar-10%0%+ 10%+ 20%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexDMAAUOur ETF tracks the IPO Index